INVESTMENTS

ATEM Capital invests in innovations across the Life Sciences industry with the promise to cure once-incurable diseases that help people live longer. Our target technologies are breakthroughs with unmet clinical need, strong IP protection, and the appeal to become a must-have for strategic players. We completed many successful transactions with a superior return on invested capital in partnerships with the leading US and EU venture groups.

LIFE CHANGING

INVESTMENTS

OUR TEAM'S

ATEA Pharmaceuticals - biopharmaceutical company Logo
ATEA Pharmaceuticals
Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases.

Atea went public at a valuation of $1.9 billion which makes over 30x of our Series A investment back in 2014 at pre-money $10 million. The company made an exclusive partnership with Roche for the ex-US rights ahead of the IPO.
NASDAQ: AVIR, IPO in Oct 2020
ATEA Pharmaceuticals - biopharmaceutical company Logo
ATEA Pharmaceuticals
Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases.

Atea went public at a valuation of $1.9 billion which makes over 30x of our Series A investment back in 2014 at pre-money $10 million. The company made an exclusive partnership with Roche for the ex-US rights ahead of the IPO.
NASDAQ: AVIR, IPO in Oct 2020
Iridia - synthetic biology company Logo
Iridia
Iridia, a synthetic biology company backed by Western Digital and LifeSci Venture Partners, is developing the world's first commercially attractive, DNA-based data storage solution with a highly parallel format.

The company's technology enables an array of nanomodules with the potential to store data at exceptionally high density.
Syndax is a clinical-stage biotech company developing an innovative pipeline of cancer therapies. Logo
Syndax Pharmaceuticals
Syndax is a clinical-stage biotech company developing an innovative pipeline of cancer therapies. The company’s CEO is Briggs W. Morrison, a managing director of MPM Capital and a former head of R&D at AstraZeneca. Syndax pipeline includes a highly selective inhibitor of the Menin–MLL binding interaction to treat acute leukemias, axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor against chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.
NASDAQ: SNDX, IPO in Feb 2016
Epic Sciences  the power of clarity Logo
Epic Sciences
Epic Sciences developed susceptible tests that molecularly characterize circulating tumor cells in the blood to open up a new way to detect cancer and personalize/monitor treatments. Epic Sciences' an unbiased approach using the Comprehensive Cancer Profiling liquid biopsy platform sees those rare cells that others miss. Epic gives cancer patients and their physicians the clear, accurate insights they need to choose the best course of therapy.
Tobira Therapeutics logo
Tobira Therapeutics
Tobira developed cenicriviroc (CVC), a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 in late-stage development for the treatment of NASH, a liver scarring disease that affects millions of people and is growing alongside the high rates of obesity and diabetes, but has no approved therapies.

In September 2016, Allergan acquired Tobira Therapeutics in a US$1.7 billion deal, or 19 times its previous market value.
Tobira Therapeutics logo
Tobira Therapeutics
Tobira developed cenicriviroc (CVC), a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 in late-stage development for the treatment of NASH, a liver scarring disease that affects millions of people and is growing alongside the high rates of obesity and diabetes, but has no approved therapies.

In September 2016, Allergan acquired Tobira Therapeutics in a US$1.7 billion deal, or 19 times its previous market value.
ATEA Pharmaceuticals - biopharmaceutical company Logo
ATEA Pharmaceuticals
Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases.

Atea went public at a valuation of $1.9 billion which makes over 30x of our Series A investment back in 2014 at pre-money $10 million. The company made an exclusive partnership with Roche for the ex-US rights ahead of the IPO.
NEXT: Iridia
NASDAQ: AVIR, IPO in Oct 2020
Iridia
Iridia, a synthetic biology company backed by Western Digital and LifeSci Venture Partners, is developing the world's first commercially attractive, DNA-based data storage solution with a highly parallel format.

The company's technology enables an array of nanomodules with the potential to store data at exceptionally high density.
NEXT: Syndax Pharmaceuticals
Iridia - synthetic biology company Logo
Syndax Pharmaceuticals
Syndax is a clinical-stage biotech company developing an innovative pipeline of cancer therapies. The company’s CEO is Briggs W. Morrison, a managing director of MPM Capital and a former head of R&D at AstraZeneca. Syndax pipeline includes a highly selective inhibitor of the Menin–MLL binding interaction to treat acute leukemias, axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor against chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.
NEXT: Epic Sciences
NASDAQ: SNDX, IPO in Feb 2016
Syndax is a clinical-stage biotech company developing an innovative pipeline of cancer therapies. Logo
Epic Sciences
Epic Sciences developed susceptible tests that molecularly characterize circulating tumor cells in the blood to open up a new way to detect cancer and personalize/monitor treatments. Epic Sciences' an unbiased approach using the Comprehensive Cancer Profiling liquid biopsy platform sees those rare cells that others miss. Epic gives cancer patients and their physicians the clear, accurate insights they need to choose the best course of therapy.
NEXT: Tobira Therapeutics
Epic Sciences  the power of clarity Logo
Tobira Therapeutics
Tobira developed cenicriviroc (CVC), a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 in late-stage development for the treatment of NASH, a liver scarring disease that affects millions of people and is growing alongside the high rates of obesity and diabetes, but has no approved therapies.

In September 2016, Allergan acquired Tobira Therapeutics in a US$1.7 billion deal, or 19 times its previous market value.
NEXT: ATEA Pharmaceuticals
Tobira Therapeutics logo

LIFE SCIENCES

Fundamental factors fuel the steady growth of the healthcare markets worldwide despite any financial vulnerabilities, with the latest years setting a new sustainable record. Both public and private healthcare costs are constantly increasing in absolute and relative terms, notwithstanding financial vulnerabilities, thus creating stable multi-billion markets and second to none investment opportunities.

WHY

Thank you!
Download ATEM’s Life Sciences industry report to learn more about healthcare's accommodative liquidity and bulletproof fundamentals
POPULATION RISE AND AGING ARE DRIVING INCREASED GOVERNMENT AND PRIVATE SPENDING
diagram, POPULATION RISE AND AGING ARE DRIVING INCREASED GOVERNMENT AND PRIVATE SPENDING
POPULATION RISE AND AGING ARE DRIVING INCREASED GOVERNMENT AND PRIVATE SPENDING
diagram, POPULATION RISE AND AGING ARE DRIVING INCREASED GOVERNMENT AND PRIVATE SPENDING
THAT FUELS UNPRECEDENTED GROWTH
diagram, THAT FUELS UNPRECEDENTED GROWTH
CONSISTENT INVESTMENTS BY VENTURE CAPITAL FIRMS IN LIFE SCIENCES* PROJECTS
* Life Sciences (LS) is composed of Pharma & Biotech and Healthcare
diagram, CONSISTENT INVESTMENTS BY VENTURE CAPITAL FIRMS IN LIFE SCIENCES* PROJECTS
ARE REWARDED IN THE NUMEROUS IPO’s
Source: PwC/NVCA Moneytree report, HBM Pharma, PitchBook
diagram, ARE REWARDED IN THE NUMEROUS IPO’s
AND EXPANDING M&A ACTIVITY BY BIG PHARMA
diagram, AND EXPANDING M&A ACTIVITY BY BIG PHARMA
AND EXPANDING M&A ACTIVITY BY BIG PHARMA
diagram, AND EXPANDING M&A ACTIVITY BY BIG PHARMA
POPULATION RISE AND AGING ARE DRIVING INCREASED GOVERNMENT AND PRIVATE SPENDING
diagram, POPULATION RISE AND AGING ARE DRIVING INCREASED GOVERNMENT AND PRIVATE SPENDING
THAT FUELS UNPRECEDENTED GROWTH
diagram, THAT FUELS UNPRECEDENTED GROWTH
CONSISTENT INVESTMENTS BY VENTURE CAPITAL FIRMS IN LIFE SCIENCES* PROJECTS
* Life Sciences (LS) is composed of Pharma & Biotech and Healthcare
diagram, CONSISTENT INVESTMENTS BY VENTURE CAPITAL FIRMS IN LIFE SCIENCES* PROJECTS
ARE REWARDED IN THE NUMEROUS IPO’s
Source: PwC/NVCA Moneytree report, HBM Pharma, PitchBook
diagram, ARE REWARDED IN THE NUMEROUS IPO’s
AND EXPANDING M&A ACTIVITY BY BIG PHARMA
diagram, AND EXPANDING M&A ACTIVITY BY BIG PHARMA
Download ATEM's Life Sciences industry report to learn more about healthcare's accommodative liquidity and bulletproof fundamentals.

OUR GAME-CHANGING

STRATEGY

Get efficient access to one of the most exciting and private asset classes of Life Sciences innovations

Landmark deal flow

of major like-minded US and Western Europe VC firms and selected private projects of successful serial entrepreneurs

Real-time insights

from the most connected Advisory Board into investment opportunities and emerging Big Pharma needs

Industrial-quality diligence

to optimize decision-making process and risk management

INVEST IN

CURES

ATEM acts in strategic partnerships with the world’s leading venture firms and possesses critical mass, topnotch expertise, industrial quality diligence, and professional board-level control to identify superior technologies with healthy returns to investors

INVESTNENT

THEMES

30% — Scientific Home-Runs

Early-stage breakthrough science managed by high-caliber serial entrepreneurs with unmatched track-record of success

40% — Next Gen Bioplatforms

Fast-growing biopharma companies with a diversified and robust pipeline and sound promise to go public or ready for M&A within one to three years

30% — Medicine Automation

Post-revenue companies in AI drug discovery, alternative care, digital therapeutics, and robotics with potential for multi-billion growth

BECOME A PART OF THE NEXT

SCIENTIFIC BREAKTHROUGH

IMMUNO-ONCOLOGY

Projects with cure ambition,
novel MoA, use of innovative
delivery platforms, and signs of efficacy

AUTOIMMUNE DISEASES

Technologies saving lives with robust preclinical and clinical data and manageable regulatory path

RARE DISEASES

Customizable therapeutics for people with genetic diseases that have no treatment or cure

NEUROLOGY

Projects that let people enjoy their life experiences, with human proof-of and a well-understood mechanism of action

OUR

LEADERSHIP

Our international team combines big picture perspective and long-term technology view with decades of diverse experience in investments, scientific research, clinical development, intellectual property, and operations.

Team
Advisory Board
Anton GOPKA
Managing Member
Elena MALEY
Managing Member
Zachar LEYKIN, M.D.
Medical Advisor
Peter STAROKADOMSKY, Ph.D.
Scientific Advisor
Yulii BOGATYRENKO
Venture Partner
Viktor KOTELIANSKY, M.D.
Scientific Advisor
Anton GOPKA, Managing Member
Anton Gopka is a Managing Member at ATEM Capital with a primary focus on private investments. Before ATEM, Mr. Gopka was managing a biotechnological venture capital fund — a US$760 million strategic partnership between Domain Associates and a sovereign technology fund. Anton was responsible for eleven private investments into high-profile US biotech development companies and managed public offerings of four companies on NASDAQ.

Before that, Mr. Gopka held senior positions in M&A advisory at Barclays Capital, Sistema JSFC (LSE: SSA), and Dresdner Kleinwort. Previous board memberships include Atea Pharmaceuticals (NASDAQ: AVIR), Marinus Pharmaceuticals (NASDAQ: MRNS), Tobira Therapeutics (NASDAQ: TBRA), and Miramar Labs (observer). Mr. Gopka received a master's degree in international economics from the Moscow State University for International Affairs (MGIMO-University), an advanced corporate finance course diploma from INSEAD, and a Board Leadership certificate from Harvard Business School.

He is a member of the US National Association of Corporate Directors (NACD) and a member of the Review Committee of the National Cancer Institute (NCI).
Elena MALEY, Managing Member
Elena Maly is a Managing Member at ATEM Capital. She has over ten years of successful investment experience in venture capital and private equity. Before ATEM,Elena was a partner at an investment firm that managed a US$0.75 billion investment partnership between Domain Associates, a US life sciences venture capital, and a sovereign high-tech fund. Also, Elena was on the board of directors of Syndax Pharmaceuticals (NASDAQ: SNDX), an immuno-oncology company. Elena studied Advanced Portfolio Management and Finance at York University, Board Leadership at Harvard Business School, and Business Law at UCSD.
Yulii BOGATYRENKO, Venture Partner
Yulii Bogatyrenko is a Venture Partner at ATEM Capital with extensive global markets expertise. Mr. Bogatyrenko has over 20 years of General Management and Business Development experience in Biopharma and Healthcare in the U.S., Europe, Latin America, and the Asia Pacific.

He is the Principal of Biopharma C&I, a biotechnology consulting firm that works with smaller private and public biotech companies in Business Development and Partnering, Financing, Commercialization and Launch Readiness and R&D Strategy. Prior to that Yulii held leadership positions in Commercial and Business Development organizations and led led large commercial franchises at Bayer, Pfizer/Wyeth and Teva Specialty business.

He successfully managed over 15 launches globally and built biopharma partnerships in the U.S., Europe, and the rest of the world. Yulii has significant experience across multiple therapeutic areas, including Oncology, Rare and Orphan, CNS, Inflammation, CV, Dermatology and other therapeutic areas. He started his healthcare career with Oxford Health in NYC, and A.T.Kearney in Cambridge, working with large payer organizations in the U.S. and Europe as well as biotech product launches, restructurings, and M&A.

Yulii holds an MBA in Finance from L. Stern School of Business, NYU.
Zakhar LEIKIN, M.D., Medical Advisor
Zakhar Leikin is a Medical Advisor at ATEM Capital and a Chief Medical Director at NovaMedica, a subsidiary of Domain Associates, a US venture capital firm. He has over 15 years of experience in clinical trials, drug development, and investments. Zakhar is Before that, Zakhar was a leading medical expert in a US$0.75 billion biotechnology fund and investment partnership between Domain Associates and a sovereign high-tech fund. He started his career as a practicing neurosurgeon and resident cardiothoracic surgeon in leading medical centers.
Joseph CAMARDO, M.D.
Bruce BURLINGTON, M.D.
Ed GODBER, MBA
Rivka KREITMAN, Ph.D.
Prof. Roberto PELLICCIARI
Prof. Victor KOTELIANSKY, M.D., Scientific Advisor
Prof. Victor Koteliansky is a Scientific Advisor at ATEM Capital. Viktor has over 40 years of experience in Life Sciences and biotechnology R&D. Previously, he was the Senior VP for Science at Alnylam Pharmaceuticals, Cambridge, MA (NASDAQ: ALNY). Before Alnylam, he spent ten years at Biogen Inc., Cambridge, MA (NASDAQ: BIIB). He has a vast global network of relations with the leading scientists in the key fields: molecular biology and genetics, RNA technologies, nano-delivery platforms, genetic engineering, immune-oncology, etc.
Peter STAROKADOMSKY, Ph.D., Scientific Advisor
Peter Starokadomsky is a Scientific Advisor at ATEM Capital. Peter is a research scientist at UT Southwestern Medical Center, one of the premier academic medical centers in the US, integrating pioneering biomedical research with exceptional clinical care and education. The institution’s faculty includes many distinguished members, including six awarded Nobel Prizes since 1985. Peter completed his postdoctoral research at the Weismann Institute of Science (Israel). His main scientific focus is in molecular immunology, immune-oncology, and rare diseases.

KNOWLEDGE

CENTER

Joseph CAMARDO, M.D.

Dr. Camardo has 30 years of global biopharmaceutical experience and extensive expertise in every stage of oncology drug development. He is Head of Medical Affairs at ADC Therapeutics (NYSE: ADCT). Before ADCT, he was Senior Vice President of Celgene Global Health. Before Celgene, Dr. Camardo was Senior Vice President of Clinical Development and Medical Affairs at Forest Research Institute and spent more than 20 years at Wyeth Research before its acquisition by Pfizer. At Wyeth, he held roles including Senior Vice President of Global Medical Affairs and Senior Vice President of Clinical Research and Development. He oversaw developing the first-ever approved antibody-drug conjugate Mylotarg™ (gemtuzumab ozogamicin) for acute myeloid leukemia, among other oncology development programs.

Dr. Camardo completed medical school at the University of Pennsylvania and is board certified in internal medicine.

Bruce BURLINGTON, M.D.
D. Bruce Burlington, M.D. is a prominent independent consultant on pharmaceutical product development and regulatory affairs with more than 30 years of experience in regulatory affairs and drug development with special interests in helping companies prepare for critical meetings with FDA, conduct product due to diligence evaluations, and set up processes, organizations, and staffing plans to achieve their regulatory obligations.

He is a Member of the Boards of Directors for AstraZeneca and Cangene.

Bruce Burlington’s extensive experience in drug and product development comprises several senior posts at Wyeth, including Executive Vice President and Worldwide Head of Regulatory Affairs, where he played a central role in developing and global registration of many products.

Before joining Wyeth, Bruce Burlington was a leader at the U.S. Food and Drug Administration (FDA), where he served for 17 years in various roles, including director of the Division of Biological Investigational New Drugs, several management positions in the Center for Drug Evaluation and Research, and director of the Center for Devices and Radiological Health.

As an infectious disease physician and a leader in regulatory policy, Bruce Burlington has served as the industry representative on the FDA’s Drug Safety and Risk Management Advisory Committee.

Bruce Burlington graduated from Louisiana Tech University with a B.A. in Psychology and Economics and received his M.D. degree from Louisiana State University.

He completed his internal medicine internship and residency and his infectious disease fellowship at the University of Colorado.

Ed GODBER, MBA

Ed Godber serves as a VP BioPharma Partnership at Guardant Health (NasdaqGS: GH), a leading precision oncology company focused on helping conquer cancer globally through the use of its proprietary blood tests, vast data sets, and advanced analytics. Before Guardant Health, he was Chief Business Officer and Executive Vice President of Life Science Ventures at PatientsLikeMe, a patient-powered research network. Before that, he was the Chief Executive Officer of the London-based Health Labs Advisory Boards, where he was a strategic advisor to pharma, biotech, venture capital, and nonprofit organizations.

He also spent nearly five years at GlaxoSmithKline (GSK) as Senior Vice President, heading up access to medicines as part of the European Executive Team and exploring evidence innovation within the research and development division. In that position, he also co-founded a multi-million dollar external scientific collaboration on real-world data.

Godber began his career in public health, strategic commissioning, and policy research in the UK’s National Health Service (NHS). He has advised a wide range of transformational ventures, including the Bill & Melinda Gates Foundation and the Chatham House Working Group on Anti-Bacterial Resistance.

He holds a master’s degree in health economics from the University of York and a master’s degree in business administration from the London Business School.

GET IN TOUCH

Rivka KREITMAN, Ph.D.

Rivka Kreitman is a Senior Partner at KRDable consulting, a strategic drug development, product evaluation, and partnerships consultancy. Also, she serves as a board member at the Philadelphia Israel Chamber of Commerce, a board member of the BrainBoost Innovation Center, and a member of the Scientific Advisory Board at Rerum Novarum, a Philadelphia based firm dedicated to the support of the university and corporate technology transfer and the global commercialization of innovation.

Before this, Rivka has been with Teva for 26 years, during which she has held many roles ranging from BD (sourcing of new projects). She was running pharmacological studies assessing the mechanism of action of Copaxone (a drug for Multiple Sclerosis), managing the North America IR&D function and the Global Clinical Operation, heading Branded Regulatory Affairs and the Global Innovative Research and Development (IR&D). Her focus is mainly on CNS, Autoimmune and Oncology, Biologics, Women’s health, Immunology, and Cell therapy. In one of her last roles at Teva, Rivka was responsible for leading the search for new products, scientific evaluation of all opportunities, and collaborating with partners on early-stage assets and technologies.

Rivka earned her Ph.D. at the Weizmann Institute of Science, Israel (Biochemistry) and postdoctoral work at Princeton University, NJ, US (Molecular Biology).

Prof. Roberto PELLICCIARI

Roberto Pellicciari is a Full Professor of Medicinal Chemistry at the University of Perugia. He was an inventor of Ocaliva®, currently marketed by Intercept Pharmaceuticals to treat Primary Biliary Cirrhosis (PBC). From 2007 to 2008, he has been President of the European Federation of Medicinal Chemistry (EFMC). Before that, Prof. Pellicciari was the President of the Division of Medicinal Chemistry of the Italian Chemical Society.


He received many awards for his research work. In 2005 he was awarded the "Giacomello" prize from the Division of Medicinal Chemistry of the Italian Chemical Society. In 2003 he was awarded the XVI Merz Professorship from the University of Frankfurt. In 1999 he was awarded the "Domenico Marotta" prize of the "Accademia Nazionale delle Scienze detta dei XL". Roberto Pellicciari has published over 300 papers and several international patents.